Current major drug therapy for T2DM can be categorized into six classes (Biguanides, Sulfonylureas, Thiazolidinediones, DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists) in addition to insulin analogs. This evidence concerns the gene INS and type 2 diabetes mellitus.